$8.31
-0.33-3.82%
Últ. Act.: Oct 23, 4:00 AM
$8.22
-0.42-4.86%
ImmunityBio (IBRX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
ImmunityBio (IBRX) publicó su última previsión de julio 25, 2025 para Q2 2025. La compañía estimó ingresos en un rango de $26.4M - $26.4M para el período.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.08 | $-0.07 | $-0.09 | $-0.10 |
| Actual | $-0.08 | $-0.08 | $-0.06 | $-0.07 |
| Surprise | +3.75% | -14.3% | +33.3% | +30.0% |
| Revenue | ||||
| Estimate | $49.0M | $43.4M | $37.5M | $31.0M |
| Actual | $51.2M | $44.2M | $38.3M | $32.1M |
| Surprise | +4.47% | +1.93% | +2.07% | +3.39% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.06 | $-0.05 | $-0.08 | $-0.08 |
| Revenue | ||||
| Consensus | $59.5M | $73.1M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $-0.08 | $-0.08 | 3.75 % |
| Q1 | May 7, 2026 | $-0.08 | $-0.07 | -14.3 % |
| Q4 | Feb 23, 2026 | $-0.06 | $-0.09 | 33.3 % |
| Q3 | Nov 4, 2025 | $-0.07 | $-0.10 | 30.0 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $51.24M | $49.05M | 4.47 % |
| Q1 | May 7, 2026 | $44.21M | $43.37M | 1.93 % |
| Q4 | Feb 23, 2026 | $38.28M | $37.51M | 2.07 % |
| Q3 | Nov 4, 2025 | $32.06M | $31.01M | 3.39 % |